<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04888182</url>
  </required_header>
  <id_info>
    <org_study_id>BBH-KU 33</org_study_id>
    <nct_id>NCT04888182</nct_id>
  </id_info>
  <brief_title>High Protein Diet and Physical Activity in COPD</brief_title>
  <official_title>The Effect of High Protein Diet in Combination With Physical Activity in the Rehabilitation of Patients With Chronic Obstructive Pulmonary Disease (COPD) at Risk of Malnutrition- a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jens Rikardt Andersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COPD outpatients with severe and very severe (grade III-IV) disease at risk of malnutrition&#xD;
      commencing rehabilitation (7-10-week physical activity program) were randomized to receive a&#xD;
      high protein diet (≥ 25 energy percentage) or standard care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral muscle function was measured by 6MWD (6-meter-walk-distance) and handgrip&#xD;
      strength; FFM was measured by bioimpedance, mid upper arm circumference, and mid-thigh&#xD;
      circumference; quality of life was measured by CAT (????); and dyspnoea was measured by the&#xD;
      Medical Research Council dyspnoea scale and Borg scores at baseline and after 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Actual">October 1, 2019</completion_date>
  <primary_completion_date type="Actual">March 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, parellel, not blinded</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6-minute walk test (6MWD)</measure>
    <time_frame>7 weeks</time_frame>
    <description>metres</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hand grip strenght</measure>
    <time_frame>7 weeks</time_frame>
    <description>kg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fat Free Mass (FFM)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Bioimpedance - kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnoea after 6 minutes walk</measure>
    <time_frame>7 weks</time_frame>
    <description>Medical Research Council (MRC) dyspnoea scale (scores range from 0 to 5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>7 weeks</time_frame>
    <description>self-administered COPD Assessment Test (CAT), 40-point scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individual nutritional guidance of a protein intake of ≥25 E%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Free diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>intervention</intervention_name>
    <description>a protein intake of ≥25 E%. An oral nutritional supplement (containing 1570 kJ/100 g and 92 g protein/100 g. Atpro 200) was used as supplement to the patients' habitual diet.</description>
    <arm_group_label>intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosed COPD stage III or stage IV&#xD;
&#xD;
          -  Nutritional risk by screening (NRS-2002)(Kondrup et al, 2002) and/or low-fat free mass&#xD;
             (FFMI) (≤ 15% for women and ≤ 16% for men) measured by Bioelectrical Impedance&#xD;
             Analysis (BIA)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Terminal phase of COPD&#xD;
&#xD;
          -  Lung transplanted patients&#xD;
&#xD;
          -  Severe Comorbidities influenzing the end-points (pancreatic insufficiency, severe&#xD;
             hepatic failure, inflammatory gastrointestinal disease)&#xD;
&#xD;
               -  Multiple sclerosis&#xD;
&#xD;
               -  Any unwillingness or inability (e.g. not able to make notes of their nutritional&#xD;
                  intake, come to consultations or manage oral intake)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens R Andersen</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pulmonary Medicine</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Jens Rikardt Andersen</investigator_full_name>
    <investigator_title>Associate Professor, Primary Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

